DEADLINES for 2015 RFPs:
*Letter of intent is due at least two weeks prior to each deadline for consideration in that funding cycle
ApoE RFP: The Alzheimer's Drug Discovery Foundation (ADDF) and the Robert A. and Renée E. Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. See full RFP.
PRECLINICAL DRUG DISCOVERY RFP: The Alzheimer's Drug Discovery Foundation (ADDF) seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive aging. See full RFP.
PACT RFP: The ADDF has created the Program to Accelerate Clinical Trials (PACT) to increase the number of innovative drugs tested in humans at the crucial proof of concept stage for Alzheimer’s disease. This program will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s. The ADDF now has funding available to consider trials budgeted at up to $3million+ per application. This increased funding will be available for a limited time only. See full RFP.
ADDF/NIH RFP: The ADDF will consider financial assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. Application deadline is rolling. See full RFP.